Table 1.

Demographic and Clinical Characteristics of Participant Groups

	HC Mean ± SD	CHR-P Mean ± SD	ESZ Mean ± SD
Demographics
Gender (% male)	56.56	52.81	67.74
Age (Range: 12–35)a	20.86 ± 6.36	18.68 ± 4.59	22.01 ± 4.56
Ethnicity (%)
White / Caucasian	58.19	56.18	51.61
Asian American	20.49	13.48	22.58
Black / African American	6.56	10.11	6.45
American Indian / Alaska Native	2.46	2.25	0.00
Native Hawaiian / Pacific Islander	1.64	3.37	2.15
More Than One Race	10.66	10.11	11.83
Not Reported	0.00	4.49	5.38
Medication (%)
Chlorpromazine equivalents (mg)	---	b c	285.34 ± 322.97b
Antipsychotic medication	---	14.61	80.65d
(typical, atypical, unknown)	---	(0, 100, 0)	(1.33, 94.67, 4.00)
Symptom Severity Ratings e
SOPS Positive	---	10.00 ± 4.88	---
SOPS Negative	---	11.76 ± 5.78	---
SOPS Disorganized	---	5.78 ± 3.89	---
SOPS General	---	8.07 ± 4.82	---
PANSS Positive	---	---	13.78 ± 4.70
PANSS Negative	---	---	16.55 ± 6.76
PANSS General	---	---	32.94 ± 8.49

Note. HC=healthy control; CHR-P=clinical high-risk for psychosis; ESZ=early illness schizophrenia; SD=standard deviation; SES=socioeconomic status; SOPS=Scale of Psychosis-Risk Symptoms; PANSS=Positive and Negative Syndrome Scale.

^aGroups were significantly different on age, F(2,303)=9.05, p<.001, with the CHR-P group significantly younger than HC (p=.011) and ESZ (p<.001) groups.

^bChlorpromazine equivalents for 11 CHR-P participants and 12 ESZ participants was missing.

^cMorphometric results showed the same pattern when medicated CHR-P patients were dropped.

^dAntipsychotic medication status for 7 participants missing.

^eSOPS Negative for 4 participants missing; SOPS Disorganized and General for 3 participants missing; PANSS scores only for UCSF participants.